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Hematopoietic cell transplantation (HCT) is a complex procedure that requires availability of adequate
infrastructure, personnel, and resources at transplantation centers. We conducted a national survey of
transplantation centers in the United States to obtain data on their personnel, infrastructure, and care de-
livery models. A 42-item web-based survey was administered to medical directors of transplantation centers
in the United States that reported any allogeneic HCT to the Center for International Blood and Marrow
Transplant Research in 2011. The response rate for the survey was 79% for adult programs (85 of 108 centers)
and 82% for pediatric programs (54 of 66 centers). For describing results, we categorized centers into groups
with similar volumes based on 2010 total HCT activity (adult centers, 9 categories; pediatric centers, 6 cat-
egories). We observed considerable variation in available resources, infrastructure, personnel, and care de-
livery models among adult and pediatric transplantation centers. Characteristics varied substantially among
centers with comparable transplantation volumes. Transplantation centers may ﬁnd these data helpful in
assessing their present capacity and use them to evaluate potential resource needs for personnel, infra-
structure, and care delivery and in planning for growth.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Approximately 20,000 patients receive autologous or
allogeneic hematopoietic cell transplantation (HCT) in the
United States each year. This number is expected to steadily
increase because of advances in transplantation technologyedgments on page 1314.
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ty for Blood and Marrow Transplantation.and supportive care, increasing donor availability, expanding
indications, andgrowth in theoverall numberof patientswith
hematologic cancers because of an aging population [1-4]. In
the present era, the majority of patients who need HCT can
ﬁnd a suitable donor. Hence, human resources, structural
constraints, and patient access barriers have emerged as
critical system capacity barriers to the anticipated need for
HCT. Human resource constraints include a projected
shortage of physicians, physician assistants, nurse practi-
tioners, nurses, pharmacists, and other health care pro-
fessionals whomake up the HCTworkforce [1,5-7]. Structural
constraints include availability of adequate facilities, efﬁcient
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to meet the demand for HCT. Key patient access barriers
include health disparities for underserved, minority, low-
income and rural populations, transportation and ﬁnancial
burdens, lack of caregiver support, and limited access to
transplantation-related patient information [1,6,8]. The
increasingnumberof transplantation survivorswill add to the
resource constraints faced by transplantation centers [9].
HCT is a complex procedure that is available through
select institutions that have the necessary expertise and
resources. However, infrastructure and resources available
at transplantation centers can vary. Centers with similar
transplantation volume may differ substantially in re-
sources and personnel. A better understanding of center
characteristics will help transplantation centers identify
opportunities for optimizing their care delivery models
and will assist centers and policy makers in planning for
the projected increase in the need for HCT. To facilitate
this, we conducted a national survey of United States
transplantation centers to obtain data on their personnel,
infrastructure, and care delivery models. This manuscript
presents the methods for the survey and highlights from
the report. The complete report is available at
www.cibmtr.org/ReferenceCenter/SlidesReports/Pages/
Index.aspx.METHODS
Survey Development and Administration
The survey was developed in consultation with content experts in
HCT and health services research. The ﬁnal instrument was a 42-item
web-based survey. Transplantation center medical directors were the
primary audience for the survey. The survey was piloted with medical
directors of 5 transplantation programs (3 adult centers, 1 combined
center, and 1 pediatric center) to evaluate its content validity and to
obtain an estimate of the time needed to complete the survey. The ﬁnal
survey was administered through web-based survey software (Survey-
Gizmo). Survey respondents were offered a $50 Visa gift card as incentive
to complete the survey. The study was conducted under guidance of the
National Marrow Donor Program’s institutional review board. The survey
was administered in 2012.
The survey was sent to transplantation centers in the United States that
reported any allogeneic HCT to the Center for International Blood and
Marrow Transplant Research (CIBMTR) in calendar year 2011. The CIBMTR is
a voluntary working group of more than 500 transplantation centers
worldwide that contribute detailed data on all consecutive HCTs to a sta-
tistical center at the Medical College of Wisconsin in Milwaukee and the
National Marrow Donor Program in Minneapolis. The CIBMTR also admin-
isters the Stem Cell Therapeutic Outcomes Database part of the C.W. Bill
Young Transplantation Program through a contract with the Health Re-
sources and Services Administration. Under the purview of this law, trans-
plantation centers in the United States are required to report outcomes for
all allogeneic HCT recipients to the CIBMTR. Hence, the CIBMTR captures
nearly all allogeneic HCT activity and the majority of autologous HCT activity
in the United States.
Some centers report data on both adult and pediatric HCT recipients to
the CIBMTR (n ¼ 41 centers in 2011). We established multiple processes to
determine whether these centers had integrated pediatric-adult programs
or separate adult and pediatric programs. Center characterizationwas based
on the age distribution of HCT recipients reported by these centers and a
survey of transplantation center data personnel and center medical di-
rectors to inquire about program organization. Centers with 1 medical di-
rector for both pediatric and adult programs were classiﬁed as integrated
programs. For centers with separate medical directors for the pediatric and
adult programs, we invited the medical director of each program to
participate in the survey.
In 2011, 172 transplantation centers in the United States reported allo-
geneic HCT to the CIBMTR and were eligible to participate in the survey.
Among these centers, 89 reported allogeneic transplantations on adult re-
cipients, 42 on pediatric recipients and, as noted above, 41 reported data on
both pediatric and adult recipients. From the latter, using the process
described above, we identiﬁed 26 centerswith separatemedical directors for
the adult andpediatric programsand15 integratedpediatric-adult programs.
Based on this assignment, the survey was administered to a total of 198United States transplantation centers (115 adult programs [89 þ 26], 68 pe-
diatric programs [42 þ 26], and 15 combined pediatric-adult programs). In-
tegratedpediatric-adult programsarenot reported in this analysis given their
small number and large variability in transplantation volume.
Survey Domains
The survey inquired about 4 domains of provider and center
characteristics:
1. Physician and health care provider characteristics (eg, number of
transplantation physicians, number of advanced practice providers
[APP], inpatient nurse stafﬁng ratio, and other personnel). Of note,
the survey inquired about mid-level providers, but we use the
preferred term APPs instead in this report.
2. Transplantation unit structure and resources (eg, availability of a
dedicated inpatient unit, number of beds for HCT, outpatient clinic
facilities, stem cell processing facilities, Foundation for the Accredi-
tation of Cellular Therapies [FACT] accreditation status, emergency
call structure, and research participation).
3. Medical care team structure and processes (eg, structure of inpatient
and outpatient medical teams, role of trainees, APPs, and other
healthcare providers, models of care for inpatients and outpatients,
critical care support, and transition of care).
4. Medical center characteristics (eg, center location, teaching status,
ownership status, hospital size, National Cancer Institute Compre-
hensive Cancer Center [NCI CCC] designation, patient population
treated).Survey Response
Center medical directors were invited to participate in the survey via e-
mail. Three reminders were sent to invitees who did not responded to the
initial invite. The study team subsequently made a phone attempt to reach
the survey invitees.
From the 183 adult and pediatric centers invited to participate in the
survey, 9 centers were deemed ineligible for analysis because they were
inactive at the time of survey administration (n ¼ 2), were part of a larger
program but reported data separately to CIBMTR (n ¼ 1), or had performed
no allogeneic HCT in the preceding 3 years (n ¼ 6). Hence, the response rate
for the survey was 79% for adult programs (85 of 108 centers) and 82% for
pediatric programs (54 of 66 centers). Nonresponding centers reported
lower HCT than responding centers (median total HCT volume in 2010 was
46 versus 101 transplantations for adult responding centers and 16 versus
25 for responding pediatric centers).
Some centers do not routinely report all autologous HCT activity to the
CIBMTR. From such centers that responded to the survey, we requested
conﬁrmation of their autologous HCT volumes for 2010. We excluded 2
centers (1 adult, 1 pediatric) whose autologous HCT volumes could not be
veriﬁed. Hence, the ﬁnal report describes characteristics of 84 adult and 53
pediatric programs.
Statistical Analysis
Based on their total autologous and allogeneic HCT volume reported to
the CIBMTR in 2010, adult centers were classiﬁed into 9 categories and
pediatric centers into 6 categories. Such categorization of similar-sized
centers together allows centers to compare themselves with peer pro-
grams and allows us to meaningfully describe center characteristics. This
paper presents the descriptive results of centers that responded to the
survey and were included in the ﬁnal analysis. Results are presented as
median and range or as count and proportion, as applicable.
RESULTS: ADULT CENTERS
Center Characteristics
The 84 adult transplantation programs that were
included in the analysis represented 11,837 transplant re-
cipients in 2010. Table 1 describes the characteristics of pa-
tients who underwent transplantation at these centers.
Centers were mostly located in privately owned institutions
(n ¼ 62, 74%; nonproﬁt 92% and for-proﬁt 8%) and were
afﬁliated with a teaching hospital (n ¼ 67, 80%). Thirty-seven
(44%) centers were afﬁliated with a NCI CCC; this varied by
center size as none of the very low volume centers (30 HCT/
year) and 88% of the very high volume centers (>300 HCT/
year) had NCI CCC afﬁliation. Most centers (n ¼ 75, 89%) had
Table 1
Demographics for Adult Transplantation Center Recipients
Variable Adult Transplantation Programs (n ¼ 84)*
30 HCT 31-50
HCT
51-70
HCT
71-100
HCT
101-130
HCT
131-160
HCT
161-200
HCT
201-300
HCT
>300
HCT
No. of centers 10 9 11 9 11 7 8 11 8
No. of autologous and allogeneic
HCT recipients
200 337 642 733 1287 996 1411 2709 3522
Recipients at the center who received
allogeneic HCT, median (IQR), %
23 (13-36) 23 (6-47) 42 (33-45) 40 (39-45) 38 (32-48) 36 (33-47) 38 (32-43) 36 (29-46) 48 (42-50)
Allogeneic HCT recipients at the center
who received myeloablative conditioning,
median (IQR), %
50 (22-86) 50 (29-63) 41 (19-64) 52 (42-75) 55 (28-73) 49 (38-68) 57 (41-65) 50 (38-64) 60 (44-68)
Allogeneic HCT recipients at the center
who received unrelated donor HCT,
median (IQR), %
0 (0-50) 38 (0-67) 64 (55-77) 65 (58-67) 57 (51-66) 63 (53-69) 54 (43-64) 58 (57-67) 63 (59-65)
Unrelated donor allogeneic HCT recipients
who received umbilical cord blood,
median (IQR), %
0 (0-50) 20 (9-25) 9 (0-24) 0 (0-9) 5 (0-47) 17 (0-28) 10 (2-25) 7 (0-15) 11 (7-16)
IQR indicates interquartile range (lower quartile [25th percentile] and upper quartile [75th percentile]).
* Based on data submitted by centers to the CIBMTR for HCT performed in calendar year 2010.
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were FACT accredited and among these, 90% were accredited
for both autologous and allogeneic transplantation.
Inpatient and Outpatient Resources
Most centers reported that they had inpatient beds
exclusively dedicated to the care of HCT recipients (n ¼ 78,
93%). Among these 78 centers, these beds were most often
located within a standalone transplantation unit (67%) and
less frequently as part of a hematology-oncology unit
(33%). As expected, the number of inpatient beds varied by
center size, with higher volume centers reporting a larger
number of beds dedicated to HCT patients (Figure 1A).
Forty-eight (57%) centers had performed an outpatient
transplantation within the preceding year, with a greater
proportion of large volume centers reporting outpatient
allogeneic HCT.
Personnel
As expected, the number of attending physicians and
APPs who participated in the clinical care of HCT recipients
varied by center size (Figure 2A,B). Of note, most programs
(n ¼ 78, 93%) used APPs to assist in the inpatient or outpa-
tient clinical care of patients. The number of transplantation
procedures performed per provider varied by center size.
Because high volume centers had more physicians who
exclusively took care of HCT recipients, they could perform
greater number of procedures per provider. We also inquired
about the full-time equivalents (FTEs) at each center for
clinical transplantation coordinators, pharmacists, and psy-
chosocial clinicians, which again varied by center size
(Figure 3A-C).
Care Delivery Models
Besides the attending physician, the inpatient care team
at most centers included APPs (n ¼ 65, 77%), pharmacists
(n ¼ 73, 87%), and/or fellow trainees (n ¼ 54, 54%). Some
centers also reported having resident trainees (n ¼ 20, 24%),
other physicians (eg, hospitalists; n ¼ 11, 13%), and other
providers, such as psychosocial clinicians or dieticians on the
inpatient rounding team. Inpatient team composition did not
vary considerably by center size.
In most centers (n ¼ 67, 80%), patients requiring venti-
lator support were cared for in a critical care unit. A greaterproportion of larger volume centers were able to keep pa-
tients needing ventilator support on the transplantation
inpatient unit (eg, 10% of 30 HCT/year centers versus 37% of
>300 HCT/year centers).
Figure 4A and B shows physician care models and the
utilization of APPs in the outpatient setting for the ﬁrst 100
days after transplantation. Physician caremodels varied from
1 physician overseeing care of a patient in the inpatient and
outpatient settings to having a rotating service for both
inpatient and outpatient settings. Most centers (n ¼ 75, 89%)
used APPs in the outpatient setting, although their roles in
patient care varied.
All centers continued to follow their allogeneic HCT re-
cipients after transplantation for an extended period of time;
they either did not discharge their patients at all or followed
their patients along with other providers. However, autolo-
gous HCT recipients were more commonly sent back to their
referring physicians; among the various center volume cat-
egories, 43% to 69% reported that autologous HCT patients
were discharged and were no longer followed at the trans-
plantation center. A long-term follow-up or chronic graft-
versus-host disease clinic/program was reported by 36%
centers.
RESULTS: PEDIATRIC CENTERS
Center Characteristics
Pediatric centers (n ¼ 53) that were included in the sur-
vey analysis represented 1811 transplant recipients in 2010
(Table 2). The majority were located in privately owned in-
stitutions (n ¼ 49, 93%; nonproﬁt 98%, and for-proﬁt 2%) and
were afﬁliated with a teaching hospital (n ¼ 49, 93%). Fifty-
three percent were afﬁliated with a NCI CCC. Most centers
(n ¼ 37, 70%) had a stem cell processing laboratory on site.
Forty-nine (93%) centers were accredited by the FACT and
nearly all of these centers (98%) were accredited for both
autologous and allogeneic transplantation.
Inpatient and Outpatient Resources
The majority of centers had inpatient beds exclusively
dedicated for the care of HCT recipients (n ¼ 49, 93%),
either within a standalone blood and marrow trans-
plantation (BMT) unit (55%) or as part of a hematology-
oncology unit (45%). Larger volume centers were more
likely to report a dedicated BMT unit (43% of 10 HCT/year
Figure 1. Number of transplantations performed in 2010 per inpatient bed. (A) Adult centers (excludes 6 centers that did not have dedicated beds for HCT patients)
and (B) pediatric centers (excludes 4 centers that did not have dedicated beds for HCT patients).
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rate BMT unit). The number of inpatient beds varied by
center size, with higher volume centers reporting a larger
number of beds dedicated for HCT patients (Figure 1B). In
comparison to adult programs, very few pediatric centers
had performed an outpatient transplantation within the
preceding year (n ¼ 10, 19%).
Personnel
Similar trends were seen as adult centers and the number
of attending physicians and APPs varied among centers
(Figure 2C,D) andmost programs used APPs to assist with the
clinical care of patients in the inpatient and/or outpatient
settings (n ¼ 51, 96%). Figure 3D, E, and F show the FTEs of
clinical transplantation coordinators, pharmacists, and psy-
chosocial clinicians at pediatric centers.Figure 2. Number of transplantations performed in 2010 per provider. (A) Adult cente
per midlevel provider (excludes 7 centers that reported no APPs), (C) pediatric cente
plantations per midlevel provider (excludes 2 centers that reported no APPs).Care Delivery Models
In pediatric centers, similar to adult centers, the attending
physician on the inpatient teamwas frequently supported by
APPs (n ¼ 45, 85%) and pharmacists (n ¼ 47, 89%). In com-
parison to adult centers, more pediatric centers reported
having a trainee on the inpatient service (fellows, 36 [68%]
centers; residents, 24 [45%] centers). Almost all centers re-
ported that patients requiring ventilator support were cared
for in a critical care unit (n ¼ 52, 98%). Physician care models
varied among centers (Figure 4C). Most centers (n ¼ 48, 91%)
used APPs to assist with the clinical care of outpatients
(Figure 4D).
Most centers continued to follow patients long-term after
transplantation. For example, although there was some
variation in follow-up practices for allogeneic HCT recipients,
70% to 100% of centers among the various center volumers, transplantations per attending physician, (B) adult centers, transplantations
rs, transplantations per attending physician, and (D) pediatric centers, trans-
Figure 3. Number of full time equivalents (FTEs) for clinical transplantation coordinators, pharmacists. and psychosocial clinicians. (A) Adult centers, transplantation
coordinator FTEs, (B) adult centers, pharmacist FTEs, (C) adult centers, psychosocial clinician FTEs, (D) pediatric centers, transplantation coordinator FTEs, (E) pediatric
centers, pharmacist FTEs, and (F) pediatric centers, psychosocial clinician FTEs.
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tients from their program or followed them periodically in
collaboration with nontransplantation providers. Centers
were more likely to discharge autologous HCT recipients
completely from the transplantation center (50% to 83%
centers among various center volume categories did not
discharge patients at all or followed them periodically after
transplantation). Compared with adult programs, more pe-
diatric programs reported the presence of a long-term
follow-up or chronic graft-versus-host disease clinic/pro-
gram (n ¼ 33, 62%).
DISCUSSION
Our study highlights considerable variation in prevalent
resources, infrastructure, personnel, and care deliverymodels among adult and pediatric transplantation centers in
the United States. In addition, these characteristics varied
substantially among centers of similar size, as categorized by
their annual transplantation volume in 2010.
The complex organization of transplantation centers may
contribute to this variation. First, resource needs may differ
based on the patient population served (eg, ratio of autolo-
gous versus allogeneic HCT, transplantation center referral
area, and how far patients have to travel). Institutional pol-
icies and organization can play a role; for example, trans-
plantation programs within standalone cancer centers may
be structured differently compared with programs inte-
grated within an acute care hospital with other medical and
surgical specialties. Hence, programs may be sharing or
competing for resources and some resources may be
Figure 4. Transplantation center attending physician care models and utilization of APPs in the outpatient care of HCT recipients. (A) Adult centers, physician care
models, (B) adult centers, APPs outpatient care models, (C) pediatric centers, physician care models, and (D) pediatric centers, APPs outpatient care models.
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exclusive (eg, competing with other cancer or noncancer
programs). Programmatic policies can impact resource uti-
lization within a program. Focus on research, outpatient
transplantations, and long-term follow-up care are examples
of factors that may determine how centers allocate re-
sources. Referral and follow-up practices may also have an
impact (whether patients are preferentially followed at the
center or sent back to their referring oncologists). External
factors outside a center’s control can impact these issues; for
example, payer mix, where the proportion of patients with
speciﬁc insurance plans at a given center may inﬂuence care
delivery and resource utilization (eg, government plans
versus private payers with bundled/contracted payments
versus capitated plans). Our ﬁndings corroborate that “oneTable 2
Demographics for Pediatric Transplantation Center Recipients
Variable Pediatric Transpla
10 HCT 1
No. of centers 7 1
No. of autologous and allogeneic HCT recipients 52 2
Recipients at the center who received allogeneic
HCT, median (IQR), %
65 (60-71) 7
Allogeneic HCT recipients at the center who received
myeloablative conditioning, median (IQR), %
63 (50-83) 7
Allogeneic HCT recipients at the center who received
unrelated donor HCT, median (IQR), %
65 (50-100) 6
Unrelated donor allogeneic HCT recipients who received
umbilical cord blood, median (IQR), %
50 (20-100) 5
* Based on data submitted by centers to the CIBMTR for HCT performed in calensize ﬁts all” approach is not possible and, in fact, should not
be recommended when considering transplantation center
characteristics. Transplantation centers have to consider and
adapt to national, local, institutional, and programmatic
policies and forces in the process of evaluating optimal re-
sources needed to successfully accommodate their trans-
plantation activity and then determine how best to organize
and utilize those resources.
Similarly, there was considerable variation in care de-
livery models among transplantation centers. This again
highlights the complex structure of transplantation pro-
grams and the innovative ways centers utilize their available
resources to take care of their patients. For example, most
centers use APPs for caring for HCT recipients but the centers
use them in different ways. Again, this likely is inﬂuenced byntation Programs (n ¼ 53)*
1-20 HCT 21-30 HCT 31-50 HCT 51-70 HCT >70 HCT
3 11 11 6 5
14 274 427 348 496
4 (58-80) 72 (60-79) 66 (54-75) 46 (34-62) 66 (61-68)
7 (60-82) 69 (55-81) 77 (56-85) 68 (59-75) 73 (67-77)
0 (43-79) 64 (50-67) 72 (67-77) 58 (51-67) 84 (65-85)
0 (20-67) 29 (17-57) 33 (21-69) 21 (5-48) 28 (21-70)
dar year 2010.
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inpatient/outpatient areas, or institutional/state policies that
dictate what APPs privileges). The caremodels also represent
the “need” for services within a program. For example, very
low volume programs may not need their hematology-
oncology physicians to dedicate all their time to the care of
HCT recipients.
We would like to highlight some caveats that have to be
considered in interpreting and using our data. First, the
survey reports resources that are presently available at
transplantation centers. It does not necessarily represent
what may be considered optimal for the number of trans-
plants performed. Second, there is considerable variation in
how transplantation centers are structured and utilize their
available resources. Two centers with the same annual
transplantation volume and comparable transplantation
outcomes could have very different resource proﬁles. Hence,
we caution using these data for “benchmarking” infrastruc-
ture and personnel for HCT centers.
Some limitations of our study have to be considered. We
performed a cross-sectional survey and inquired about
prevalent resources and personnel. Centers could be
recruiting personnel or in the process of expanding their
facilities and this was not captured by our survey. Because
some providers may not dedicate all their time to the clinical
care of HCT recipients (eg, work part-time or spend time
doing research or taking care of nontransplantation pa-
tients), the actual transplantation speciﬁc FTEs of physicians
and APPs at centers may be lower than their total number.
We focused on personnel who are required for the direct
clinical care of patients and we did not capture data on all
personnel. Other personnel are critical for the successful
operation of a transplantation program, such as data man-
agers and quality personnel who are required to maintain
and comply with regulatory and accreditation requirements
for transplantation programs. Low-volume centers were less
likely to respond to the survey; however, with an 81%
response rate, our study has an adequate representation of
centers of all sizes. Finally, a survey can only provide a high
level overview of center characteristics and resources. More
research is needed to better understand transplantation
program structure and care delivery models at a more
granular level.
With the projected increase in need for HCT, trans-
plantation centers have to consider capital investment in
resources, infrastructure, and personnel to ensure that they
have sufﬁcient capacity to handle the growing number of
transplantation recipients. Data from our survey will assist
transplantation centers and policy makers in this process.
Centers can compare their characteristics with other trans-
plantation centers with similar transplantation volumes and
evaluate whether there are opportunities for optimizing
infrastructure and/or personnel.
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